Citizens Reaffirms Ratings for Celcuity, Alphabet, and Allogene

Citizens has reiterated its stock rating for Celcuity ahead of a drug launch. The firm also reaffirmed its rating for Alphabet, citing the strength of its YouTube platform, and for Allogene, based on progress in its clinical trials.